NewGene Clinical Services

In response to NHS England’s recent Strategy and Service Specification for the future of Genomics services in England, Newcastle Teaching Hospitals, Leeds Teaching Hospitals, Sheffield Children’s Trust, Sheffield Teaching Hospitals and NewGene have come together as the Yorkshire and North East Genomic Hub (GeNEQ); an exciting collaboration to provide services for Genomics across Yorkshire and Humber and the North.

NewGene will continue to receive samples and perform genomic tests as part of this collaboration. We will issue further information about the future genomic testing arrangements as it becomes available.

NHS England are currently producing the National Genomic Test Directory that will specify which genomic tests are commissioned by the NHS in England, the technology by which they are available, and the patients who will be eligible to access to a test. The final draft 2018/2019 National Genomic Test Directory for rare and inherited disorders and cancer can be accessed at

As the current services transition, tests may periodically fall outside of our locally accredited scope. With the support of UKAS, we will work to secure an extension to scope application as part of this process. We will continue to offer the same high quality service on a regional rather than a local basis, working with our partner laboratories. Further detail will be provided.

Financial arrangements for the period of October 2018 to end of March 2019 will be unaffected by this process. Therefore where tests are currently invoiced on a per test basis this will continue. From April 2019 it is anticipated that all Cancer genetic testing will be considered in tariff and laboratory services will invoice the referring Trust for tests requested. More detail will be provided once it becomes available.

Medulloblastoma sub-typing assay launched

Improving the quality of care delivered to patients

NewGene are delighted to announce availability of an innovative clinical assay to perform molecular sub-typing in cases of medulloblastoma, the most frequently occurring paediatric brain tumour. Developed in collaboration with Professor Steve Clifford and his colleagues at Newcastle University, the test utilises the Agena Bioscience MassARRAY platform to identify characteristic patterns of gene methylation in biopsy samples. This information can provide valuable guidance to clinical teams as they consider the best course of treatment for individual patients.

Additional information about the test and how to submit samples is available

on the medulloblastoma sub-typing page.

PROSPECT-NE: Bringing state of the art tumour profiling to the region

NewGene are part of a project to deliver crucial cancer research

In many areas of cancer we are seeing advances that allow the delivery of personalised or precision medicine with novel agents specifically targeted at the genetic changes causing disease. The PROSPECT-NE study is harnessing the expertise in next generation DNA sequencing at NewGene to enable the Sir Bobby Robson Cancer Trials Research Centre to continue to play a leading role in the development of new cancer treatments.

From December 2017 patients referred to the trials unit will be offered the opportunity to have their tumours profiled to identify any mutations in a panel of genes known to be associated with cancer. This will support signposting of the patients to appropriate clinical trials and add to the knowledge base on the causes of cancer.

To find out more about PROSPECT-NE please click this link.

Industry Focus:

Biomarkers in Personalised Medicine: discovery and delivery

Writing in The Biochemist, NewGene contribute to the conversation on the challenges of biomarker discovery and implementation in a clinical setting.

Click here to view a pdf of the article.

The great success of NewGene User Group Meetings

Over the course of the spring months NewGene have held a number of user group meetings, bringing together our customers, regional clinical experts and the NewGene team to discuss the state of the art in each clinical field and to define how to implement service development and best practice to the processes in our region.

  • EGFR User group meeting, sponsored by Astra Zeneca
  • RAS User group meeting, sponsored by Merck Serono
  • Haematology User group meeting, sponsored by NewGene

Contact us

NewGene Limited
Bioscience Building
International Centre for Life
Newcastle upon Tyne

Tel: +44 (0)191 242 1923
Fax: +44 (0)191 241 8799

Click here for location map

Mon – Fri 08:30 to 17:00, closed Bank Holidays

An ISO 15189 accredited Medical Laboratory company

NewGene Limited | Company Number: 06735445

Technology Partners

Agilent Technologies

Agena Bioscience


Sophia Genetics



Enquiry form